Search Within

GDMT, Medicine

Formats
  1. Journal Article (916)
  2. Meeting Abstract (825)
  3. Review (46)
  4. Book Section (38)
  5. Editorial (28)
  6. Guidelines (18)
  7. Correspondence (7)
  8. Research Letter (1)
Groups
  1. Gynecology Disease Management Team (1879)
  2. Department of Medicine (1870)
  3. Solid Tumor Oncology Division (1868)
  4. Gynecologic Medicine Service (1828)
  5. Surgery (576)
  6. GDMT, Surgery (462)

More Groups

People
  1. Carol Aghajanian (607)
  2. Martee Hensley (289)
  3. Nadeem Abu-Rustum (277)
  4. Roisin O'Cearbhaill (271)
  5. Vicky Makker (263)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (42)
  2. 2024 (159)
  3. 2023 (165)
  4. 2022 (196)
  5. 2021 (146)
  6. 2020 (173)

More Years

Publications
  1. Gynecologic Oncology (416)
  2. Journal of Clinical Oncology (414)
  3. International Journal of Gynecological Cancer (148)
  4. Annals of Oncology (106)
  5. Clinical Cancer Research (61)
  6. Cancer (37)

More Publications

Publishers
  1. Elsevier Inc. (494)
  2. American Society of Clinical Oncology (445)
  3. Lippincott Williams & Wilkins (173)
  4. American Association for Cancer Research (136)
  5. Oxford University Press (128)
  6. Nature Publishing Group (71)

More Publishers

Results (1879)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Germline variants in non- BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival
    Meeting Abstract

    Kahn, R. M.; Selenica, P.; Boerner, T.; Xiao, Y.; Sia, T.; Sheehan, M.; Zhou, Q.; Iasonos, A.; Grisham, R. N.; O'Cearbhaill, R. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial
    Meeting Abstract

    Leath, C. A.; Deng, W.; Mell, L. K.; Richardson, D. L.; Walker, J. L.; Holman, L. L.; Lea, J. S.; Amarnath, S. R.; Santos-Reyes, L. J.; Arend, R. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types
    Meeting Abstract

    Carlo, M. I.; Schroeder, A.; Mukherjee, S.; Kemel, Y.; Kotecha, R. R.; Lee, C. H.; Shah, N. J.; Feldman, D. R.; Liu, Y. L.; Walsh, M. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers
    Meeting Abstract

    Liu, D.; Makker, V.; Buonocore, D. J.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Johnson, A.; Offin, M.; Solit, D. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study
    Meeting Abstract

    Moore, K. N.; Sabanathan, D.; Du, Y.; Duan, H.; Li, X.; Wang, F.; Marathe, O.; Yang, H.; Makker, V.; Growdon, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer
    Meeting Abstract

    Yap, T. A.; Elhaddad, A. M.; Grisham, R. N.; Hamm, J. T.; Marks, D. K.; Shapiro, G.; Le Corre, C.; Li, J.; Lin, T. T.; Liu, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis
    Meeting Abstract

    Elkrief, A.; Nicholas, W.; Smith, N.; Dai, A.; Slingerland, J. B.; Aleynick, N.; Lumish, M. A.; Giardina, P.; Chaft, J. E.; Chapman, P. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial
    Meeting Abstract

    Harter, P.; Trillsch, F.; Okamoto, A.; Reuss, A.; Kim, J. W.; Rubio-PeĢrez, M. J.; Vardar, M. A.; Scambia, G.; Tredan, O.; Nyvang, G. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results
    Meeting Abstract

    Meric-Bernstam, F.; Makker, V.; Oaknin, A.; Oh, D. Y.; Banerjee, S. N.; Martin, A. G.; Jung, K. H.; Lugowska, I. A.; Manso, L.; Manzano, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The highs and lows of serous ovarian cancer
    Review

    Grisham, R. N.; Manning-Geist, B. L.; Chui, M. H.
    Cancer (2023)

    Fulltext@MSK | Save